Chewy (CHWY) Q1 2026 earnings review
Record Margins, Smaller Promises
Chewy's Q1 was a tale of two statements. The P&L was excellent: net sales grew 7.7% to $3.36 billion, adjusted EBITDA jumped 31% to a record $253 million (7.5% margin, +130 bps), and GAAP net income rose 52% to $94.8 million. But the outlook took the spotlight: management cut its full-year sales guidance to $13.40-13.55 billion, citing a consumer that weakened late in the quarter, while keeping the 6.6-6.8% adjusted EBITDA margin guide intact. The company also reshaped its balance sheet: $200 million of buybacks, the SmartPak and Modern Animal acquisitions, and a first-ever $600 million Term Loan B launched today.
🐂 Bull Case
Adjusted EBITDA margin expanded 130 bps with a 25% incremental flow-through, driven by Sponsored Ads, mix, and 90 bps of SG&A leverage. Management held the full-year margin guide despite the revenue cut and absorbing a dilutive Modern Animal acquisition.
With Modern Animal closed, Chewy jumps from 18 to 47 vet clinics, targeting ~60 by year-end with ~$290 million of steady-state revenue. About 40% of clinic customers are new to Chewy and reach ~$900 first-year spend, roughly 1.5x the company average.
🐻 Bear Case
Cutting the full-year sales outlook this early signals limited visibility. Stripping ~$150 million of acquired revenue (SmartPak + Modern Animal), organic growth at the midpoint is only ~5.7%, versus 8.3% in FY2025.
Cash fell from $860 million to $485 million in one quarter after $200 million of buybacks and the $175 million SmartPak deal, and Chewy is now adding $600 million of term debt. The capital structure is shifting from net-cash simplicity to a leveraged M&A posture.
⚖️ Verdict: ⚪
Neutral. The margin and cash flow execution is genuinely impressive, and holding the EBITDA guide while cutting revenue speaks to a durable earnings algorithm. But a first-quarter guidance cut, five straight quarters of decelerating Autoship growth, and a pivot to debt-funded M&A keep us from getting bullish until the consumer stabilizes.
Key Themes
Consumer Cracked Late in the Quarter
Management saw premiumization and discretionary attach rates weaken in the back half of Q1, driven partly by elevated fuel prices, and chose to stop underwriting a second-half consumer recovery. Reported NSPAC growth slowed to 2.4% (4.6% normalized for last year's extra week), down from ~5% in mid-2025, and net customer adds are now expected at the lower end of the 150,000-250,000 quarterly range. One inconsistency worth noting: the CEO's release quote cites 'nearly 200,000 net customer additions,' while the presentation and balance of active customers (21.497M vs 21.327M) show 170,000. Two product initiatives meant to accelerate second-half growth (Autoship line attachment, new ad bidding algorithms) are working but being muted by the macro.
Autoship Growth Has Decelerated for Five Straight Quarters
Autoship remains the backbone at a record 84.4% of net sales, but its growth rate has stepped down every quarter for over a year: 14.8% in 25Q1 to 10.5% now. Because Autoship is the company's most predictable revenue, its deceleration is the cleanest read on the underlying slowdown, and it contradicts the framing of purely 'transitory' headwinds. Decelerating.
Modern Animal Triples the Vet Clinic Footprint
Chewy Vet Care is the fastest NSPAC compounder in the portfolio, and the Modern Animal acquisition (closed just after quarter-end) takes Chewy from 18 clinics to 47, with 10-12 organic openings planned for ~60 by year-end. Combined steady-state revenue is pegged at ~$290 million, expanding Chewy's reach into a ~$54 billion pet healthcare TAM. Modern Animal is EBITDA-dollar neutral in 2026 but a modest margin-rate drag, heaviest in Q2. Customer acquisition through clinics is proving unusually cheap: the Chewy brand alone pulls in high-quality traffic with minimal local marketing.
Sponsored Ads and 'Chewy Max' Doing the Margin Heavy Lifting
Sponsored Ads exited FY2025 around 2% of sales against a 1-3% long-term entitlement, with roughly two-thirds to 70% of revenue dropping to the bottom line. The new Chewy Max product, which speeds advertiser onboarding and solves cold-start problems for smaller brands, was tried by ~40% of advertisers in the quarter. Management explicitly credits ads with offsetting the fuel surcharge costs now embedded in the P&L. This remains the single largest structural gross margin lever on the path to the 10% EBITDA target.
AI Savings on Track: Low Tens of Millions This Year, $50M+ Next
AI is being embedded in customer service, pharmacy operations, fulfillment, and marketing workflows, and management reconfirmed both the low-tens-of-millions benefit for fiscal 2026 and the $50 million+ target for fiscal 2027. These savings showed up in Q1's 90 bps of SG&A leverage alongside fulfillment automation. In a quarter where revenue guidance fell, cost-side execution is what protected the margin guide: efficiency actions planned for the back half were pulled forward.
First-Ever Term Debt: $600M Term Loan B
Chewy launched a $600 million Term Loan B on the morning of the report, a deliberate evolution from its historically debt-free balance sheet, with a stated target of net leverage below 2x adjusted EBITDA. The move follows a quarter in which cash fell by $375 million on buybacks and the SmartPak acquisition, and precedes the Modern Animal payment. Guidance now embeds $10-15 million of net interest expense versus net interest income previously. Reasonable at these leverage levels, but it removes a layer of downside protection just as the consumer is softening.
Inventory Built $128M in a Single Quarter
Inventories rose 16.5% sequentially to $1.01 billion, with $128 million of organic build consuming operating cash (a year ago, inventory released $30 million), well ahead of 7.7% sales growth. Part of the balance sheet increase reflects acquired SmartPak inventory, but the cash flow statement confirms a large organic build. Plausible explanations include buy-ahead of cost increases or stocking for new categories, but management didn't address it, and it bears watching against the softer demand backdrop. If sales decelerate as guided, this inventory either gets promoted away or sits.
Q2 Margin Cadence: MAP Lap and Fuel Surcharges
Q2 gross margin will contract year over year as Chewy laps non-recurring MAP pricing benefits from 25Q2 (last year's 30.4% was an artificial high point), and fuel surcharges represent a mid-single-digit million headwind to the quarter. That's why Q2 EBITDA margin guidance of 6.3-6.4% implies only ~50 bps of expansion versus Q1's 130 bps. Management frames this purely as phasing, with stronger expansion returning in H2, which is now a key checkpoint for the full-year margin guide.
Other KPIs
Active customers reached 21.5 million, up 3.6% YoY. Sequential adds of 170K were consistent with recent quarters but came in at the low-to-mid end of the 150-250K framework, and management now expects the lower end going forward rather than the previously assumed back-half acceleration. Stable, with churn improving and reactivations healthy; the softness is concentrated in new-to-Chewy acquisition.
Up 45% YoY on $108.5 million of operating cash flow and flat capex of $37.7 million. The quality is decent but flattered relative to net income trends by working capital: the $128 million inventory build was largely offset by an $84 million increase in trade payables. LTM free cash flow now stands at $585 million against $129 million of LTM capex, comfortably funding the dividend-free, buyback-heavy capital return model even after the new interest expense.
A meaningful step up from 19.9% a year ago, and full-year guidance of 24-26% compares with 16-18% guided for FY2025. This is a structural GAAP earnings headwind now that valuation allowances are exhausted: pre-tax income grew 69% but net income grew 52%. Investors anchoring on adjusted EPS ($0.43, +23% YoY) should note the tax drag embedded in GAAP comparisons going forward.
Guidance
Decelerating. Implies 6.3-7.5% growth versus 8.3% in FY2025, and the range includes ~$80 million from SmartPak and ~$70 million from Modern Animal, so organic growth at the midpoint is roughly 5.7% (derived). Management cut the outlook from its original (undisclosed magnitude) plan, explicitly removing the previously assumed second-half consumer acceleration. The low end assumes conditions worsen from here; the high end assumes improvement.
Accelerating on dollars. Maintained despite the revenue cut and the Modern Animal margin drag, implying ~$900 million of adjusted EBITDA at the midpoints, up roughly 25% YoY after 26% growth in FY2025. The ~100 bps of expansion is funded by Sponsored Ads, SG&A leverage, and AI efficiencies pulled forward from the back half. Holding this guide is the quarter's strongest statement of confidence.
Decelerating. Implies 6.3-7.3% growth, down from 7.7% in Q1, and assumes the consumer behavior seen exiting Q1 simply persists. Combined with the full-year range, implied second-half growth is roughly 5-8% including the Modern Animal contribution, meaning organic H2 growth near the low end would mark the slowest stretch since fiscal 2024.
Decelerating expansion. Chewy is introducing quarterly EBITDA margin guidance for the first time, a welcome transparency step. The guide implies ~50 bps of YoY expansion versus 130 bps in Q1, held back by the MAP pricing lap and fuel surcharges, with stronger expansion guided for H2. Q2 adjusted diluted EPS of approximately $0.36 implies ~9% YoY growth, a sharp slowdown from Q1's 23%.
Diluted share count guidance was lowered by 5 million shares, reflecting the $200 million Q1 buyback pace. The swing from net interest income to $10-15 million of expense reflects the Term Loan B, and the 24-26% tax rate is a structural step up from FY2025's 16-18%. Share-based compensation is expected broadly flat YoY at roughly $311 million, still a hefty ~2.3% of sales.
Key Questions
Term Loan B Use of Proceeds
You launched $600 million of debt the morning of the print but never specified what it funds: Modern Animal consideration, accelerated buybacks, or general purposes. What is the intended allocation, and what return threshold justifies borrowing while the consumer is weakening?
170K vs 'Nearly 200K' Customer Adds
The press release quote cites nearly 200,000 net customer additions while the presentation shows 170,000 net sequential adds. Which figure reflects the quarter, and what explains the gap, gross adds timing, definitional differences, or rounding?
Inventory Build Rationale
Organic inventory grew $128 million in the quarter, against a softening demand outlook. How much is buy-ahead of cost inflation versus new category stocking, and what is the markdown risk if the low end of the sales guide materializes?
Modern Animal Synergy Bridge
The deal is EBITDA-dollar neutral in 2026 with a margin drag concentrated in Q2. What is the quantified path to accretion in 2027, and how do mature four-wall clinic margins compare with CVC-built locations?
Clinic Capex Trajectory
Scaling from 18 to ~60 clinics while capex was flat at $37.7 million in Q1 seems inconsistent with prior CVC build costs. How much clinic-related capex is embedded in the FY2026 plan, and does the free cash flow trajectory hold as openings accelerate?